We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AKESF market cap is 7.62B. The company's latest EPS is CNY 2.3425 and P/E is 3.76.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 70.88M | 0 | 225.63M | 837.66M | 4.53B |
| Operating Income | -247.87M | -954.23M | -1.28B | -1.38B | 1.73B |
| Net Income | -335.39M | -1.18B | -1.07B | -1.68B | 2.03B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 1.67B | 3.86B | 4.81B | 5.5B | 9.18B |
| Total Liabilities | 1.46B | 405.73M | 1.53B | 2.95B | 4.66B |
| Total Equity | 215.71M | 3.45B | 3.28B | 2.55B | 4.52B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -219.6M | -617.78M | -1B | -1.24B | 2.47B |
| Investing | -127.89M | -555.7M | -579.59M | -889.75M | -4B |
| Financing | 1.23B | 2.88B | 1.59B | 1.49B | 960.89M |
| Market Cap | 7.62B |
| Price to Earnings Ratio | 3.76 |
| Price to Sales Ratio | 1.68 |
| Price to Cash Ratio | 4.94 |
| Price to Book Ratio | 1.69 |
| Dividend Yield | - |
| Shares Outstanding | 865.86M |
| Average Volume (1 week) | 1.14k |
| Average Volume (1 Month) | 2.01k |
| 52 Week Change | 45.21% |
| 52 Week High | 10.12 |
| 52 Week Low | 4.30 |
| Spread (Intraday) | 1.7 (17%) |
| Company Name | Akeso Inc (PK) |
| Address |
floor 4, willow house grand cayman KY1-9010 |
| Website | https://www.akesobio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
